Funding shortfall
The company has no revenue and needs additional capital to continue development and operations.
- Scope
- Equity, debt, ATM, collaborations
- Materiality
- high
ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a U.S.-based biopharmaceutical company developing antibody therapies and therapeutic vaccines for neurodegenerative and other protein-misfolding diseases. Its research platform uses protein biology, physics, and supercomputing to identify disease-specific epitopes and design selective therapeutics and diagnostics, with a focus on Alzheimer’s disease, multiple system atrophy, and ALS.
0.88
0.88
| % | |
|---|---|
| Antibody therapeutics | 40% Selective antibodies designed to target toxic misfolded proteins in neurodegenerative disease. |
| Therapeutic vaccines | 25% Vaccine candidates intended to generate immune responses against disease-specific protein conformations. |
| Discovery platform | 20% Computational and protein-biology tools used to identify disease-specific epitopes and candidates. |
| Diagnostics research | 10% Research efforts aimed at detecting toxic misfolded proteins for disease identification. |
| Collaborative licensing potential | 5% Potential future value from collaborations, licenses, or strategic transactions. |
ProMIS does not sell commercial products today; its near-term counterparties are research partners, clinical...
- Pharmaceutical collaboration partnersprimary
Potential partners that may license assets, fund development, or co-develop programs.
- Clinical investigators and trial sitesprimary
Hospitals and research centers that enroll patients and generate clinical data for PMN310 and other programs.
- Regulatory agenciessecondary
Agencies that review safety, biomarker, and efficacy data before any approval path.
- Future neurology patientsemerging
Patients with Alzheimer’s disease, MSA, ALS, and other protein-misfolding disorders.
ProMIS is headquartered in the United States and its disclosures are presented in U.S. dollars...
- •Headquartered in the United States
- •Financial reporting and cash balances are in U.S. dollars
- •Clinical and research activity is centered on neurology programs
- •Geography is driven by trial sites and partner locations, not sales
- •No country-level revenue disclosed because the company has no revenue
ProMIS is focused on advancing its lead Alzheimer’s program PMN310 while continuing to build a pipeline across other...
01
Advance PMN310 clinical developmentshort-term
The lead Alzheimer’s asset is central to the company’s value creation and partnering potential.
02
Broaden the pipeline across protein-misfolding diseasesmedium-term
A broader portfolio can reduce single-asset dependence and expand partnering options.
03
Secure non-dilutive or dilutive fundingshort-term
Development-stage biotech requires ongoing capital to fund trials and regulatory work.
The company faces the typical risks of development-stage biotechnology, including clinical failure, regulatory...
Going-concern uncertainty
Management disclosed substantial doubt about the ability to continue as a going concern.
- Scope
- Near-term liquidity and operations
- Materiality
- high
Clinical development failure
Drug candidates may not show sufficient safety or efficacy in preclinical or clinical studies.
- Scope
- PMN310 and other pipeline assets
- Materiality
- high
Internal control weakness
A material weakness can delay reliable reporting and undermine investor confidence.
- Scope
- Financial reporting and controls
- Materiality
- medium
Regulatory and commercialization risk
Even successful candidates require approvals, manufacturing readiness, and market access.
- Scope
- Future product launch
- Materiality
- high
Research and development accruals
Affects operating expenses and liabilities
Share-based compensation
Affects operating loss and equity
Going-concern assessment
Affects financial statement presentation and risk perception
Equity financing accounting
Affects equity balances and financing cash flow presentation
: 29.4.2026